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Background: Fluticasone furoate nasal spray (FFNS) is a glucocorticoid developed for the treatment of
allergic rhinitis (AR). This study aimed to assess the safety, efﬁcacy, and systemic exposure of FFNS in
Japanese children with perennial AR (PAR).
Methods: In this multicentre, open-label, phase 3 study, 61 children aged 2 to <15 years were treated
with FFNS 55 mg, once daily for 12 weeks. Nasal and ocular symptoms were scored by parents/guardians/
patients and recorded in a patient's daily diary. In addition, rhinoscopy ﬁndings, including mucosal
swelling, were scored by the investigators as an efﬁcacy measure. As a safety measure, adverse events
and clinical laboratory data were evaluated.
Results: An adverse event was reported by 67% of patients during the treatment and follow-up period, all
of which were mild in intensity. The most commonly reported adverse events were nasopharyngitis and
acute sinusitis (acute rhinosinusitis). There were no serious adverse events. FFNS 55 mg improved nasal
symptom scores and rhinoscopy ﬁndings compared with the baseline. Ocular symptom scores were also
improved compared with the baseline in FFNS 55 mg in a sub-group of patients with any ocular symp-
toms at baseline. FFNS 55 mg was shown to be well tolerated over the 12-week treatment period. Ma-
jority of patients receiving FFNS 55 mg had unquantiﬁable plasma levels of ﬂuticasone furoate (FF).
Conclusions: Twelve-week treatment with FFNS 55 mg, once daily, is well tolerated and effective with low
systemic exposure in Japanese children aged 2 to <15 years with PAR.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Allergic rhinitis (AR) is the most common chronic condition in
children, and its prevalence has been increasing in most countries.1
The prevalence of AR in children in Japan is approximately 30%,2,3
which is similar to that in adults. In younger age children, aged
0e4 years, prevalence of AR is low but signiﬁcant proportion,
especially in perennial AR (PAR) (i.e., 4.0%). AR is characterized by
symptoms of sneezing, rhinorrhea, nasal congestion, and nasal
itching,2,3 and is often associated with ocular symptoms.1 Accord-
ing to the allergic rhinitis and its impact on asthma (ARIA) guide-
lines,1 AR is intermittent or persistent in duration and mild ork and Sensory Organ Science,
l, 1-1-5 Sendagi, Bunkyo-ku,
ety of Allergology.
rgology. Production and hosting by Elsmoderate/severe in intensity. The Japanese guidelines2,3 classify AR
as PAR or seasonal AR (SAR) depending on the timing and duration
of symptoms. Common allergens of PAR include dust mites, animal
dander, molds, and cockroaches, and allergens of SAR include Jap-
anese cedar pollens, ragweed, and orchard grass.4 The Japanese
guidelines use a unique scoring system based on frequency of
symptoms in a day, including episodes of paroxysmal sneezing and
episodes of nose blowing, to rate AR severity (mild, moderate, se-
vere, and most severe).2,3 This scoring system was used as an efﬁ-
cacy measure in this study.
AR in children has a signiﬁcant impact on the quality of life
(QOL), sleep, and school performance.5 Cognitive dysfunction
related to AR itself can impair the performance of school children
with AR6. Some studies have shown that ocular symptoms also
deteriorate patients' QOL, and some patients consider ocular
symptoms to be more annoying than nasal symptoms.7,8 In addi-
tion, if left untreated, comorbid conditions associated with AR,
including asthma and otitis media, can be problematic in children.9evier B.V. All rights reserved.
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ease.1,10 In Germany, the average annual cost of SAR is 1089 V per
child or adolescent and 1543 V per adult.1
Anti-inﬂammatory therapy with corticosteroids to effectively
control the nasal symptoms of AR is well established, and inter-
national guidelines recommend intranasal corticosteroids (INS) as
ﬁrst-line therapy for patients with all but the mildest symptoms.1
The Japanese guidelines recommend INS as the most effective
medication to improve symptoms of AR2,3. INS has a broad spec-
trum of efﬁcacy for a range of nasal symptoms, including conges-
tion, rhinorrhea, and sneezing.1e3 In addition, INS has been
reported to improve eye symptoms accompanying AR.11,12
Fluticasone furoate nasal spray (FFNS) is a glucocorticoid
developed for the treatment of AR, and is administered using a
unique, side-actuated device.13 This delivery system was designed
for ease of self-administration, as well as for convenient parent or
caregiver administration to children.14 As a treatment for AR, FFNS
is currently approved for use in more than 100 countries including
Europe and United States. FFNS is approved for use in patients as
young as 2 years of age with AR in the United States and 6 years of
age in Europe.
Although well studied in healthy volunteers and patients with
AR, including non-Japanese children aged 2e11 years with PAR or
SAR,15,16 the clinical efﬁcacy, safety, and systemic exposure of FFNS
in Asian children, including Japanese children, have, to our
knowledge, not been investigated. Therefore, we conducted two
clinical studies to evaluate the efﬁcacy and safety of FFNS 55 mg in
Japanese children. One study was a two-week, randomized, phase
III study to assess the efﬁcacy and safety of once-daily FFNS 55 mg
compared with placebo in Japanese children aged 6 to <15 years
with PAR, which has been reported in this journal.17 (The Clinical-
Trials.gov Identiﬁer: NCT01630135, GlaxoSmithKline protocol
number: FFR116364.) In this article, we report the results of the
other study, a twelve-week, open-label, phase III study to assess the
safety, efﬁcacy, and systemic exposure of once-daily FFNS 55 mg in
Japanese children aged 2 to <15 years with PAR.
Methods
Study design
This phase 3, multicenter, open-label study was conducted in 6
centers in Japan. Eligible patients entered a 1e2-week screening
period and those meeting the criteria were assigned to the treat-
ment, FFNS 55 mg. Treatment was administered once daily in the
morning for 12weeks, and patients attended a clinic every 4weeks.
A follow-up visit/phone call was scheduled one week after the end
of the treatment. Patients who completed all of their visits
including the follow-up were deemed to have completed the study.
Patients who were assigned to a treatment and discontinued study
before the completion had early withdrawal visit to assess safety
and efﬁcacy at the end the treatment.
Patients
Eligible patients were aged 2 to <15 years with 6 months
history of PAR, and had positive speciﬁc immunoglobulin E (IgE)
antibody tests to PAR allergens (i.e., positive to at least one house
dust mite or house dust allergen), elevated nasal eosinophil counts,
and a 3 total nasal symptom scores (3TNSS) of 3 at baseline.
Patients were excluded from the study if they had symptoms of
SAR due to pollen present in their geographic area during the study
participation, had a co-morbid disorder that could affect the result
of the study (e.g., acute/chronic sinusitis, nasal polyps, upper res-
piratory or eye infection), had a co-morbid disease that couldthreaten their safety (e.g., tuberculosis, infection without effective
antibacterials, serious hepatic/renal/cardiac/pulmonary dysfunc-
tion or hematopoietic disorder, uncontrolled hypertension/dia-
betes mellitus, or asthma [except for mild intermittent cases]), or
used medications that could affect the efﬁcacy outcome of the
study (e.g., systemic corticosteroids within 8 weeks of the study).
Use of any medication for allergic rhinitis, other than the study
medication, and any concomitant medication that could affect the
efﬁcacy outcome of the study (e.g., corticosteroids) was prohibited
during the screening and treatment periods.Safety assessments
The primary safety endpoints were frequency and severity of
adverse events. Adverse events were monitored during the treat-
ment and follow up periods. Safety of FFNS was also assessed by
laboratory tests (hematology and clinical chemistry). Blood sam-
ples (e.g. hematology, clinical chemistry, IgE) were analyzed at
central laboratories. Treatment compliance was assessed through
patient diary cards.Efﬁcacy assessments
Efﬁcacy values included 3TNSS, 4TNSS, total ocular symptom
scores (TOSS), individual nasal and ocular symptom scores, troubles
with daily life score, rhinoscopy ﬁndings, and overall evaluation of
response to therapy. Parents/guardians/patients were instructed to
record patients' symptom scores (individual nasal and ocular
symptoms and troubles with daily life) in a diary every day during
the screening and treatment periods. Each baseline value was an
average of values obtained on 4 consecutive days prior to
randomization. Investigators scored rhinoscopy ﬁndings at baseline
(randomization) and at each visit during the treatment period.
Parents/guardians/patients and investigators evaluated the overall
response to therapy at the end of the treatment period.
3TNSS is the sum of individual 4-point scores for sneezing
(number of episodes of paroxysmal sneezing in a day: 0 ¼ 0 time;
1¼1e5 times; 2¼ 6e10 times; 3¼11 times), rhinorrhea (number
of episodes of nose blowing in a day: 0 ¼ 0 time; 1 ¼ 1e5 times;
2 ¼ 6e10 times; 3 ¼ 11 times), and nasal congestion (0 ¼ none;
1 ¼ nasal congestion without oral breathing; 2 ¼ severe nasal
congestion causing occasional oral breathing in a day; 3 ¼ severe
nasal congestion causing prolonged oral breathing in a day). 4TNSS
is the sum of individual 4-point scores for sneezing, rhinorrhea,
nasal congestion, and nasal itching (0 ¼ none; 1 ¼ minimal
awareness of the symptom; 2 ¼ deﬁnite awareness of symptom
that is tolerable [between 3 and 1]; 3¼ severe symptom that causes
interference with activities of daily living). TOSS is the sum of in-
dividual 4-point scores for eye itching, tearing, and eye redness,
which were scored as follows: 0 ¼ none; 1 ¼minimal awareness of
the symptom; 2 ¼ deﬁnite awareness of symptom that is tolerable
(between 3 and 1); 3 ¼ severe symptom that causes interference
with activities of daily living. Troubles with daily life score was
scored as follows: 0 ¼ no trouble; 1 ¼ few troubles with daily life;
2 ¼ Intermediate between 3 and 1; 3 ¼ painful and complicating
daily life. Rhinoscopy ﬁndings included swelling of the inferior
turbinate mucosa (0 ¼ none; 1 ¼ possible to see the center of the
middle turbinate; 2 ¼ between 3 and 1; 3 ¼ impossible to see the
middle turbinate) and quantity of nasal discharge (0 ¼ none;
1¼ small amount adhered; 2¼ between 3 and 1; 3¼ ﬁlled). Overall
evaluation of response to therapy assessed the change in AR
symptoms from the baseline on a 7-point score (7 ¼ signiﬁcantly
worse; 4 ¼ no change; 0 ¼ signiﬁcantly improved). The nasal
symptoms (sneezing, rhinorrhea, and nasal congestion) and
Table 2
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tical Guideline for the Management of Allergic Rhinitis in Japan.2,3
Pharmacokinetic assessments
Pharmacokinetic analysis of blood samples collected at 0.5e2 h
after the last dose (end of the treatment period) was undertaken to
determine plasma concentrations of ﬂuticasone furoate (FF).
Plasma concentration of FF was determined by liquid chromatog-
raphy with tandem mass spectrometry analysis at a central labo-
ratory. FF was extracted from human plasma by solid phase
extraction using an isotopically labeled internal standard. The
lower limit of quantiﬁcation for FF was 10 pg/mL.
Statistical analyses
Sample size of 59 patients can detect an adverse event rate of 5%
with statistical power of 95%. To obtain 59 evaluable patients, 60
patients was planned to be assigned to the treatment.
Safety analyses were performed in patients who received at
least one dose of study medication (the safety population [SP]).
Efﬁcacy analyses were performed in patients whowere assigned
to the treatment, received at least one dose of the studymedication,
and completed at least one diary assessment of 3TNSS after taking
the study medication (the full analysis set [FAS]). The efﬁcacy data
are expressed as mean and standard deviation (SD) or as frequency
distributions. For TOSS, analysis was performed for the sub-group
of patients with baseline TOSS >0.
Pharmacokinetic (PK) analyses were performed in patients
whose blood sample were taken for pharmacokinetic analyses and
measured (PK concentration population).
To investigate the safety and efﬁcacy of FFNS in younger age
group (2 to <6 years), sub-group analysis (2 to <6 years and 6 to
<15 years) was performed for efﬁcacy measure of 3TNSS and
rhinoscopy ﬁndings, safety measure of frequency and severity of
adverse events, and pharmacokinetic analysis.
Ethical approval and clinical trial registration
The study was conducted in accordance with the Declaration of
Helsinki (2008) and Good Clinical Practice guidelines. The institu-
tional review boards of each center approved the protocol of this
study. Written informed consent was obtained from parents or
guardian of all participating children. Assent was obtained from all
children aged 12 years and above. All children under 12 years old
were provided with information about the study depending on
their understandings and assent was obtained where appropriate.
The ClinicalTrials.gov Identiﬁer is NCT01622231. GlaxoSmithKline
protocol number is FFR116365.Table 1
Subject demographics (SP).
FFNS 55 mg
(N ¼ 61)
Age (years) Mean ± SD 8.0 ± 3.59
MineMax 2e14
Gender, n (%) Male 42 (69%)
Female 19 (31%)
Race, n (%) Japanese 61 (100%)
Duration of PAR, n (%) <2 years 14 (23%)
2 to <5 years 26 (43%)
5 years 21 (34%)
SP, safety population; FFNS, ﬂuticasone furoate nasal spray; PAR, perennial allergic
rhinitis.Results
Study population
Of the 72 patients screened in the study, 61 patients received
FFNS 55 mg. All of the 61 patients were included in the analysis of
safety and efﬁcacy (SP and FAS). Of the 61 patients treated, 59 pa-
tients (97%) completed the study and 2 patients prematurely
withdrawn from the study. The reasons for withdrawal were
withdrawal of consent and investigator discretion.
The demographic and baseline characteristics for the SP are
summarized in Table 1. All patients were of Japanese heritage.
Average agewas 8.0 years. Duration of PAR was at least two years in
77% of patients. In the IgE test, all patients were positive for all of
the four PAR allergens, two house dust mite allergens and two
house dust allergens stated in the inclusion criterion. Mean base-
line 3TNSS was 4.5, indicating that the study population consisted
mainly of moderate cases. Themean compliance to study treatment
was 98.34%.
Safety and tolerability
Safety and tolerability analyses were conducted in the SP
comprising 61 patients aged 2 to <15 years. Treatment with FFNS
55 mg was well tolerated over the 12-week treatment period. All
adverse events reported during the study were mild in intensity.
The proportion of patients with at least one adverse event was 67%
(n¼ 41) and of similar frequency across the two age groups, 2 to <6
years (74%, 14/19 subjects) and 6 to <15 years (64%, 27/42 subjects).
Themost frequently reported adverse events observed in this study
were nasopharyngitis and acute sinusitis (acute rhinosinusitis).
There was no serious adverse event and no reports of death. No
patient withdrew as a result of a drug-related or drug-unrelated
adverse event. A drug-related adverse event was reported by one
(2%) patient, who developed dysphonia (hoarseness) during the
treatment period (day 76). This event was reported in a male
subject aged 11 years, was mild in intensity, and resolved two days
after the end of the treatment. Adverse events reported with 3%
incidence are listed in Table 2. Clinical laboratory results did not
show any ﬁndings of clinical concern for clinical chemistry or
hematology.
Efﬁcacy
Efﬁcacy analyses were performed in the FAS population of 61
patients aged 2 to <15 years. FFNS 55 mg improved nasal symptomsAdverse events with 3% incidence in total during the treatment and follow-up
periods (SP).
Number of patients (%)
FFNS 55 mg
Age: <6 years
(N ¼ 19)
Age: 6
years
(N ¼ 42)
Total
(N ¼ 61)
Nasopharyngitis 5 (26%) 10 (24%) 15 (25%)
Acute sinusitis (acute rhinosinusitis) 5 (26%) 3 (7%) 8 (13%)
Bronchitis 1 (5%) 2 (5%) 3 (5%)
Streptococcal infection 2 (11%) 1 (2%) 3 (5%)
Otitis externa 1 (5%) 1 (2%) 2 (3%)
Eczema 0 2 (5%) 2 (3%)
Heat rash 2 (11%) 0 2 (3%)
Arthropod sting 0 2 (5%) 2 (3%)
Pyrexia 1 (5%) 2 (5%) 3 (5%)
SP, safety population; FFNS, ﬂuticasone furoate nasal spray.
Table 3
Mean change from baseline in 3TNSS and 4TNSS (FAS).
FFNS 55 mg
3TNSS 4TNSS
Age: <6 years
(N ¼ 19)
Age: 6 years
(N ¼ 42)
Total
(N ¼ 61)
Total
(N ¼ 61)
Baseline Mean (SD) 4.1 (1.07) 4.7 (1.26) 4.5 (1.22) 5.3 (1.53)
Entire treatment
period
Mean change (SD) 2.1 (1.33) 2.2 (1.78) 2.2 (1.65) 2.6 (2.01)
Week 3e4 Mean change (SD) 2.4 (1.51) 2.5 (1.99) 2.5 (1.84) 2.9 (2.26)
Week 7e8 Mean change (SD) 2.4 (1.51) 2.3 (2.02)y 2.4 (1.86)z 2.8 (2.26)z
Week 11e12 Mean change (SD) 1.8 (1.68) 2.1 (2.24)y 2.0 (2.07)z 2.3 (2.50)z
3TNSS, three total nasal symptom score; 4TNSS, four total nasal symptom score; FAS, full analysis set; FFNS, ﬂuticasone furoate nasal spray.
y n ¼ 41.
z n ¼ 60.
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over the entire treatment period in 3TNSS was 2.2 (Table 3). In
addition, decrease from baseline in 3TNSS was observed in FFNS
55 mg in Weeks 3e4, 7e8, and 11e12 (Table 3). The decrease from
baseline in 3TNSS was ﬁrst observed on day 1 and persisted
throughout the 12-week treatment period. Decrease in 4TNSS and
all of the four nasal symptoms were also observed in FFNS 55 mg
compared with the baseline in Weeks 3e4, 7e8, and 11e12, and
over the entire treatment period (Tables 3 and 4).
Efﬁcacy analyses of 3TNSS were performed in sub-groups
divided by age (2 to <6 years and 6 to <15 years), and demon-
strated a similar decrease from baseline over the entire treatment
period in both groups (2 to <6 years: 2.1, 6 to <15 years: 2.2).
The rhinoscopy ﬁndings of swelling of the inferior turbinate
mucosa (Fig. 1A) and quantity of nasal discharge (Fig. 1B) demon-
strated improvement in FFNS 55 mg compared with the baseline.
The proportion of patients who scored '3' (impossible to see middle
turbinate) on swelling of inferior turbinate mucosa score decreased
from baseline: 23% at the baseline, 2% onWeek 4, 0% onWeek 8, 2%
on Week 12/early withdrawal. The proportion of patients who
scored '0' (None) on quantity of nasal discharge score increased
from baseline: 7% at the baseline, 50% on Week 4, 48% on Week 8,
and 56% on Week 12/early withdrawal.
Efﬁcacy analyses of rhinoscopy ﬁndings were also performed in
sub-groups divided by age (2 to <6 years and 6 to <15 years), and
demonstrated a similar improvement from baseline in both groups
(data not shown).
Efﬁcacy analyses of ocular symptoms were performed in sub-
group of patients with baseline TOSS >0 (36 patients). Mean
baseline TOSS was 1.2, indicating that the study population con-
sisted mainly of patients with mild ocular symptoms. TOSS was
reduced from the baseline in Weeks 3e4, 7e8, 11e12, and over the
entire treatment period in FFNS 55 mg (Table 5).
Quality of life (QOL) assessment was performed using the
troubles with daily life score. The troubles with daily life score over
the entire treatment period decreased from baseline in FFNS 55 mg
(baseline: 1.1, entire treatment period decreased: 0.6).Table 4
Mean change from baseline in each individual symptom score over the entire
treatment period (FAS).
FFNS 55 mg (N ¼ 61)
Rhinorrhea Nasal
congestion
Sneezing Nasal
itching
Baseline Mean (SD) 1.6 (0.58) 1.4 (0.74) 1.5 (0.55) 0.8 (0.61)
Entire
treatment
period
Mean change
(SD)
0.8 (0.65) 0.8 (0.66) 0.7 (0.74) 0.4 (0.58)
FAS, full analysis set; FFNS, ﬂuticasone furoate nasal spray.The overall response to therapy was assessed by parents/
guardians/patients and investigators. Most parents/guardians/pa-
tients (92%) and investigators (92%) rated the overall response to
therapy as improved (i.e., “signiﬁcantly improved”, “moderately
improved” or “mildly improved”).
Pharmacokinetics
Plasma samples were collected 0.5e2 h post-dose at the end of
the 12-week treatment period and analyzed from 59 patients who
completed the study. Pharmacokinetic assessment showed that the
majority of patients receiving FFNS 55 mg did not have quantiﬁable
(lower limit of quantiﬁcation: LLQ ¼ 10 pg/mL) plasma levels of FF
(2 to <6 years [89.5%], 6 to <15 years [92.5%]; Table 6). Plasma
concentrations of FF in patients with quantiﬁable levels were 10.9
and 13.1 pg/mL in the 2 to <6 years group, and 14.9e23.7 pg/mL in
the 6 to <15 years group.0
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Table 5
Mean change from baseline in TOSS (sub-group analysis in FAS: baseline TOSS >0).
FFNS 55 mg
(N ¼ 36)
Baseline Mean (SD) 1.2 (1.06)
Entire treatment period Mean change (SD) 0.5 (1.21)
Week 3e4 Mean change (SD) 0.4 (1.26)
Week 7e8 Mean change (SD) 0.4 (1.52)y
Week 11e12 Mean change (SD) 0.6 (1.27)y
TOSS, total ocular symptom score; FAS, full analysis set; FFNS, ﬂuticasone furoate
nasal spray.
y n ¼ 35.
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The objectives of this multicentre open-label clinical study were
to evaluate primarily the safety of FFNS 55 mg, once daily over a
period of 12 weeks, and secondarily the efﬁcacy and systemic
exposure of FFNS in Japanese pediatric subjects aged 2 to <15 years
with PAR.
The safety ﬁndings of this study show that FFNS 55 mg, once
daily, was well tolerated in Japanese children aged 2 to <15 years
old, with no adverse events of moderate to severe intensity. An
event of dysphonia was considered by an investigator to be an
adverse event related to FFNS 55 mg. Although mild local nasal re-
actions including mild irritation and epistaxis are well-known
common side effects of INS, these events were not reported in
this study. The adverse events observed in the 2e5 years group
were all mild in intensity and were not considered to be related to
FFNS 55 mg, indicating that FFNS 55 mg was well tolerated in chil-
dren as young as 2 years. In clinical studies in non-Japanese chil-
dren aged 2 to<12 years, FFNS 55 and 110 mg had similar AE proﬁles
to the placebo.15,16 In these studies FFNS 55 and 110 mg were re-
ported to be well tolerated, which is consistent with the results in
this study. The absence of quantiﬁable plasma levels of FF in most
patients 0.5e2 h after the last dose in the 12-week treatment
period demonstrates low systemic exposure of FFNS 55 mg. The
percentage of patients with quantiﬁable plasma levels of FF in the
2e5 years group was low and comparable to that in the 6e14 years
group, indicating low systemic exposure both in older and younger
children as young as 2 years. The absence of quantiﬁable plasma
levels of FF in most children after 2 or 12 weeks of FFNS 55 and
110 mgwas reported in a clinical study in non-Japanese children,15,16
which is consistent with the results in this study. In adult non-
Japanese healthy male and female volunteers, bioavailability of
FFNS was assessed as low, 0.5%. The pharmacokinetic results in this
study are of value in view of the limited reports assessing systemic
exposure of recently developed INS in patients with AR in Asia
including Japan.
INS is known to have a broad spectrum of efﬁcacy for a range of
nasal symptoms, including congestion, rhinorrhea, and sneezing,
and is recommended for both sneezing and rhinorrhea type andTable 6
Plasma concentration of FF at 0.5e2 h after the last dose (PK concentration
population).
Number of patients (%)
FFNS 55 mg
Age: <6 years
(N ¼ 19)
Age: 6 years
(N ¼ 40)
NQ (<10 pg/mL) 17 (89.5%) 37 (92.5%)
10 to <20 pg/mL 2 (10.5%) 2 (5.0%)
20 to <30 pg/mL 0 1 (2.5%)
30 pg/mL 0 0
FF, ﬂuticasone furoate; FFNS, ﬂuticasone furoate nasal spray; NQ, not quantiﬁable.nasal blockage/combined type in the Japanese guideline.2,3 In this
study, FFNS 55 mg, once daily over a 12-week treatment period
improved 3TNSS, 4TNSS, and all of the four nasal symptoms of
sneezing, rhinorrhea, nasal congestion, and nasal itching compared
with the baseline. The reduction in 3TNSS in the 2e5 years group
was similar to that in the 6e14 years group, indicating that FFNS
55 mg is effective both in older and younger children as young as 2
years. Our ﬁnding of improvement in nasal symptoms in FFNS 55 mg
is in agreement with previous ﬁndings in non-Japanese children
with PAR where reduction in reﬂective total nasal symptom scores
(rTNSS) was signiﬁcantly greater in FFNS 55 mg compared with
placebo.15
Many global studies have investigated the efﬁcacy of INS using
patient-rated symptom scores but not investigator-rated symptom
scores. In this study, both patient/parent/guardian-rated subjective
nasal symptoms and investigator-rated objective rhinoscopy ﬁnd-
ings were assessed. Rhinoscopy scores are mentioned in the Japa-
nese guideline2,3: swelling of the inferior turbinate mucosa,
quantity of nasal discharge, color of the inferior turbinate mucosa,
and quality of nasal discharge. Of these four scores, swelling of
inferior turbinate mucosa and quantity of nasal discharge scores
can be used to assess changes in severity. This study showed a
reduction in rhinoscopy scores of mucosal swelling and nasal
discharge compared with the baseline, which is consistent with the
reduction noted in patient/parent/guardian-rated scores of nasal
congestion and rhinorrhea. In clinical studies in Japanese adults,
FFNS 110 mg improved both patient-rated symptom scores and
investigator-rated objective nasal symptom scores.18
AR is often associated with ocular symptoms.1 INS is reported to
be effective in improving ocular symptoms associated with AR in
adolescents and adults.11,12 In children, studies investigating the
effects of INS on ocular symptoms are limited, especially in
PAR.19e21 In this study, TOSS was reduced in FFNS 55 mg compared
with the baseline in a sub-group analysis in Japanese children with
PAR who had baseline TOSS >0. This is the ﬁrst study investigating
the efﬁcacy of FFNS for ocular symptoms in children aged 2 years
with PAR in 12 weeks treatment. We have reported the efﬁcacy of
FFNS for ocular symptoms in children aged 6 years with PAR in 2
weeks treatment.17 Further study is needed to conﬁrm the efﬁcacy
of FFNS for ocular symptoms in children with PAR.
In this study, the troubles with daily life score as QOL assess-
ment, and the overall response to therapy by parents/guardians/
patients and investigators showed improvements in FFNS 55 mg. It
is considered that improvements in nasal and ocular symptoms
resulted in improvements in these scores.
Limitations of the present study include its single-arm, open-
label design, which can affect endpoints including patient/parent/
guardian-rated and investigator-rated nasal symptom scores. In
addition, sample size, 60 subjects, is too small to detect infrequent
adverse events, and the lack of placebo or comparator does not
permit comparison of the frequency of adverse events. Also, the
baseline TOSS value was not considered as an inclusion criterion
and the baseline TOSS value was small, which made it difﬁcult to
evaluate efﬁcacy of FFNS on the basis of TOSS.
In conclusion, the results of this multicentre, open-label study
suggested that FFNS 55 mg, once daily, was well tolerated and
effective with low systemic exposure for the treatment of PAR in
Japanese children aged 2 to <15 years old.
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